The purpose of this study is to study the safety and effects of two new immunotherapies aimed at achieving and maintaining tumor shrinkage in patients with non-microsatellite stable colorectal cancer without liver metastases.

Botensilimab (also known as AGEN1181) and balstilimab (also known as AGEN2034) are both experimental drugs, which means that neither have been approved by the U.S. Food and Drug Administration (FDA).

This is a study for patients with Non-Hodgkin Lymphoma (NHL) who have relapsed or refractory disease after receiving a CD19+ CAR T cell therapy or are ineligible to receive CD19+ CAR T cell therapy.

The primary purposes of this study are to assess the safety and tolerability of escalating doses of the study drug, MT-601, and to assess the anti-tumor activity or effectiveness of MT-601 against lymphoma. 

MT-601 is considered investigational and is not yet approved by the U.S. Food and Drug Administration (FDA).

The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with multiple myeloma (MM) who have had an autologous hematopoietic stem cell transplant (AHCT) and have already received lenalidomide as maintenance therapy.
   
The study drug iberdomide is designed to target and destroy proteins that produce myeloma cancer cells. By destroying these proteins, iberdomide may prevent the cancer from returning or getting worse. This research study is being done because currently there is no effective treatment for this type of condition.

This clinical trial is for adult participants 50 years of age or older who are not currently suspected of having cancer and do not have a personal history of invasive solid tumor or hematologic malignancy (blood cancer) within the past 3 years.
   

This clinical trial is for adult participants who have newly diagnosed multiple myeloma (MM).
   
The purpose of this study is to see if the drugs Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by the investigational drug JNJ-68284528 (cilta-cel) is safe and useful for treating participants with newly diagnosed multiple myeloma, as compared with the use of VRd followed by Lenalidomide and Dexamethasone (Rd) therapy.
   

This clinical trial is for adult participants who have metastatic pancreatic cancer and have been given prior chemotherapy with FOLFIRINOX (5FU + leucovorin + irinotecan + oxaliplatin).

The purpose of this study is to test the safety of a study drug called KRT-232 (AMG 232) when used in combination with a standard treatment regimen for relapsed or refractory multiple myeloma. The standard treatment is with the drugs carfilzomib, lenalidomide, and dexamethasone (KRd).

The purpose of this study is to compare mogamulizumab alone to using Hu5F9-G4 (magrolimab) plus mogamulizumab for the cutaneous T-cell lymphomas (CTCL), Mycosis Fungoides and Sezary Syndrome, as well as determining if the addition of Hu5F9-G4 could slow or stop the cancer’s growth or prevent it from returning.
   

The purpose of this study is to learn about the effects of the study drug tofacitinib for moderately to severely active ulcerative colitis (UC) in pediatric patients. Tofacitinib is a drug that affects the immune system. The immune system normally fights infection, but in diseases like UC, the immune system may be overactive or act incorrectly, leading to a chronic inflammation in the digestive tract (colon). Tofacitinib may be able to control disease activity, improve symptoms and keep up normal, every-day functions and activities.

The purpose of this study is to test the effectiveness of the drugs cabozantinib with nivolumab and ipilimumab in rare genitourinary (GU) cancers that have no standard treatment options.